YINGLONG: A Multicenter, Prospective, Non-Interventional Study Evaluating the Safety and Tolerability of Ticagrelor in Chinese Patients with Acute Coronary Syndrome

ConclusionsTicagrelor was well tolerated with a low rate of PLATO-defined major bleeding events in Chinese ACS patients. Safety results were consistent with the known ticagrelor profile.Trial RegistrationClinicalTrials.gov identifier, NCT02430493.FundingAstraZeneca Investment (China) Co., Ltd.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research